As per the March 2022 publication from the Centers for Disease Control and Prevention, chronic diseases afflict 60% of U.S. adults. The escalating prevalence, encompassing cancer and chronic lung diseases, underscores the vital role of transfection technologies in advancing treatments. Innovations addressing chronic diseases contribute to the growing healthcare demand, and the growth of the transfection market and its pivotal role in shaping future therapeutic interventions.
Frequently Asked Questions
The market is segmented based on , By Type Transient Transfection, Stable Transfection), Methods Non-Viral Methods, Viral Methods), CRISPR Transfection Methods Non-Viral Methods, Viral Methods), Products Reagent & Kits, Instrument, Software), Organism Mammalian Cells, Plants, Fungi, Virus, Bacteria), Types of Molecule Plasmid DNA, Small Interfering RNA siRNA), Proteins, DNA Oligonucleotides, Ribonucleoprotein Complexes RNPs), Others), Application In Vitro Application, In Vivo Application, Bioproduction, Others), Stage Research, Preclinical, Clinical Phases, Commercial), End User Biopharma, Contract Research Organizations CROs), Contract Manufacturing Organization/ Contract Development and Manufacturing Organization CMOs/CDMOs), Academia, Hospitals, Clinical Labs, Others), Distribution Channel Direct Tender, Retail Sales, Others) – Industry Trends and Forecast to 2032
.
The Global Transfection Market size was valued at USD 1.30 USD Billion in 2024.
The Global Transfection Market is projected to grow at a CAGR of 9.64% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa , Brazil, Argentina and Rest of South America.
